NanoViricides Inc., a clinical-stage pharmaceutical company specializing in nanomedicine-based antiviral therapies, will present at the D. Boral Capital Inaugural Global Conference in New York City. The company's President and Executive Chairman, Anil R. Diwan, will host investor meetings, highlighting the firm's advanced drug development pipeline.
The company's lead drug candidate, NV-387, represents a significant advancement in broad-spectrum antiviral treatments. Designed to potentially address multiple viral infections including RSV, COVID-19, Long COVID, influenza, and MPOX/Smallpox, this candidate demonstrates the company's innovative approach to viral treatment strategies.
NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials, signaling potential breakthrough treatment options for respiratory viral infections. The company's unique host-mimetic nanomedicine technology offers a promising alternative to traditional antiviral approaches.
In addition to NV-387, the company is developing NV-HHV-1 for treating Shingles, further expanding its diverse therapeutic portfolio. By leveraging proprietary technology licensed from TheraCour Pharma, Inc., NanoViricides is positioning itself as a potential leader in specialized antiviral drug development.
The upcoming conference presentation provides an opportunity for investors and industry observers to gain insights into the company's technological innovations and strategic objectives in combating viral infections.
